Express Pharma

Ajanta Pharma posts Q4 and FY 2016 results

1

Revenue from operations grew 14 per cent at Rs 426 crores against Rs 372 crores in Q4 FY 2016

The board of directors of Ajanta Pharma has posted Q4 and FY 2016 results. Revenue from operations grew 14 per cent at Rs 426 crores against Rs 372 crores in Q4 FY 2016. The company had reported an EBITDA growth of six per cent at Rs 141 crores against Rs 133 crores and EBITDA was at 33 per cent of revenue. Profit before tax grew 14 per cent at Rs. 131 crore against Rs 115 crore and profit after tax grew 43 per cent at Rs 106 crores against Rs 74 crores, PAT at 25 per cent of the revenue during the said period.

The consolidated revenue from operations grew 17 per cent at Rs 1,728 crores against Rs 1,474 crores. EBITDA growth of 15 per cent at Rs 581 crores against Rs 505 crores was reported and EBITDA was 34 per cent of the revenue. Profit before tax grew 20 per cent at Rs 547 crores against Rs 456 crores and profit after tax grew 30 per cent at Rs 401 crores against Rs 310 crores. PAT was at 23 per cent of revenue.

Comments are closed.